Compugen Advances Cancer Research with First Patient Dosed in Clinical Trial for COM503 and Zimberelimab Compugen has made a significant stride in cancer treatment with the first patient dosed in a clinical trial for COM503 and Zimberelimab. This innovative approach targets advanced solid tumors.

Compugen Advances Cancer Research with First Patient Dosed in Clinical Trial for COM503 and Zimberelimab #Israel #Compugen #Holon #COM503 #Zimberelimab